Black Diamond Therapeutics, Inc. (BDTX) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BDTX Revenue Growth
Revenue Breakdown (FY 2025)
BDTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
BDTX Revenue Analysis (2017–2025)
As of May 6, 2026, Black Diamond Therapeutics, Inc. (BDTX) generated trailing twelve-month (TTM) revenue of $70.0 million. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, BDTX's historical revenue data shows various trends over time.
Revenue diversification analysis shows BDTX's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), AUPH (+20.4% YoY), and ARVN (-0.3% YoY). Compare BDTX vs KYMR →
BDTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BDTXCurrent | $70M | - | - | - | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 AUPH | $283M | +20.4% | +41.4% | 37.1% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% |
BDTX Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $12.5M | - |
| 2024 | $0 | - | $0 | - | $-78,781,000 | - |
| 2023 | $0 | - | $-437,000 | - | $-86,460,000 | - |
| 2022 | $0 | - | $0 | - | $-92,828,000 | - |
| 2021 | $0 | - | $0 | - | $-126,872,000 | - |
| 2020 | $0 | - | $0 | - | $-69,570,000 | - |
| 2019 | $0 | - | $-47,000 | - | $-8,904,000 | - |
| 2018 | $0 | - | $-44,000 | - | $-8,904,000 | - |
| 2017 | $0 | - | $-24,000 | - | $-4,119,000 | - |
See BDTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BDTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BDTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBDTX — Frequently Asked Questions
Quick answers to the most common questions about buying BDTX stock.
Is BDTX's revenue growth accelerating or slowing?
BDTX TTM revenue: $70M. YoY growth: N/A. 5-year CAGR: N/A.
What is BDTX's long-term revenue growth rate?
Black Diamond Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is BDTX's revenue distributed by segment?
BDTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.